Instead of focusing on quarterly gyrations so much, its better to look at slightly longer term trends. Glenmark Pharma business had dipped by 40% in Q2FY23 due to inventory correction on part of Glenmark Pharma, and the current sales revival is just normalization of inventory.
More importantly, non-Glenmark business is growing at a healthy pace and it is very diversified across a large customer base, which gives them some degree of pricing flexibility.
| Subscribe To Our Free Newsletter |
